Oral Tebipenem for Complicated UTI: What’s at Stake in the June 2026 FDA Decision?

Oral tebipenem (tebipenem pivoxil hydrobromide, or HBr) is the first oral carbapenem under FDA review for complicated urinary tract infection, with a decision due on or before June 18, 2026. The pending answer matters for hospitalization avoidance and antimicrobial stewardship in primary care.

April 26, 2026 · 4 min read

Why Oral Tebipenem Is in the News Right Now

Oral tebipenem returned to the FDA’s queue in December 2025 when GSK resubmitted a New Drug Application (NDA) that the agency had turned down in 2022. The new submission is supported by the global Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025.

The Prescription Drug User Fee Act (PDUFA) decision is expected on or before June 18, 2026. If approved, tebipenem HBr would become the first oral carbapenem antibiotic available in the United States.

For family physicians, the question is no longer whether oral therapy can match intravenous (IV) carbapenems for complicated UTI — PIVOT-PO answered that. The harder question is how the FDA will weigh outpatient access against legitimate antimicrobial stewardship concerns about preserving the carbapenem class.

The Background

Complicated UTI (cUTI) refers to UTI in patients with structural or functional urinary tract abnormalities, immunocompromise, urinary catheters, or pyelonephritis. The U.S. burden is substantial — about 2.9 million cases annually and more than $6 billion in direct healthcare costs, according to figures cited in the PIVOT-PO sponsor materials.

Carbapenems (ertapenem, meropenem, imipenem-cilastatin) are reserved for sepsis or for infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), but all currently require IV administration — usually meaning hospitalization or outpatient parenteral antibiotic therapy (OPAT).

Tebipenem pivoxil hydrobromide is an oral pro-drug of tebipenem. The FDA has granted it Qualified Infectious Disease Product (QIDP) and Fast Track designations. Spero Therapeutics licensed worldwide rights, excluding certain Asian territories, to GSK in 2022.

Oral Tebipenem Evidence at a Glance

Two pivotal trials anchor the file. ADAPT-PO (NEJM 2022) randomized 868 patients to oral tebipenem 600 mg every 8 hours versus IV ertapenem 1 g once daily. It met its noninferiority endpoint, but the FDA issued a complete response letter (CRL) in June 2022 citing concerns about how trial participants had been classified.

PIVOT-PO (NCT06059846) was the response. The global, double-blind Phase 3 trial randomized 1,690 hospitalized adults with cUTI or acute pyelonephritis to oral tebipenem 600 mg every 6 hours or IV imipenem-cilastatin 500 mg every 6 hours for 7–10 days. Stopped early for efficacy and presented at IDWeek 2025, the trial showed:

Overall response at test-of-cure: 58.5% (tebipenem) vs 60.2% (imipenem-cilastatin); adjusted difference −1.3% (95% CI, −7.5% to 4.8%) — meeting the prespecified 10% noninferiority margin.
Clinical cure: 93.5% vs 95.2%; adjusted difference −1.6% (95% CI, −4.7% to 1.4%).
Microbiological response: 60.3% vs 61.3%; adjusted difference −0.8% (95% CI, −6.9% to 5.3%).
ESBL-positive Enterobacterales infections: response rates were consistent with the overall population.
Most common adverse events: mild-to-moderate diarrhea and headache; no new safety signals.

Development was supported in part by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response.

Where Experts Disagree

Two views co-exist among infectious disease specialists. Supporters frame oral tebipenem primarily as a hospitalization-avoidance tool. Tony Wood, chief scientific officer at GSK, summarized the access argument:

“Oral options for drug-resistant infections are limited.” — Tony Wood, Chief Scientific Officer, GSK (October 2025 press statement)

Cautioners worry about stewardship. The Infectious Diseases Society of America (IDSA) reserves carbapenems for serious resistant infections, and a broad outpatient label could accelerate selection of carbapenem-resistant Enterobacterales (CRE).

A 2025 editorial in Contagion Live noted that tebipenem HBr in vitro minimum inhibitory concentrations against Pseudomonas aeruginosa exceed 4 μg/mL, raising questions about real-world activity at tolerated oral doses against that pathogen. The 2021 IDSA guidance on ESBL-E, CRE, and difficult-to-treat Pseudomonas remains the dominant antibiotic-selection framework, and any oral carbapenem rollout will need a clearly defined place in that hierarchy.

The Practical Question for Clinicians

For family physicians, the practical question is whether — and when — to use oral tebipenem if approved. Today, most uncomplicated UTIs are managed with nitrofurantoin, fosfomycin, or trimethoprim-sulfamethoxazole, with fluoroquinolones increasingly de-prioritized due to safety warnings and resistance. When pyelonephritis or ESBL-E is identified, hospital admission for IV therapy or OPAT is often the only realistic option.

Approval would not change first-line empiric therapy for uncomplicated UTI. The realistic use case is targeted: a hemodynamically stable patient with culture-confirmed ESBL-producing E. coli or Klebsiella who would otherwise be admitted for IV ertapenem. In that scenario, oral therapy could shorten or avoid hospitalization.

Documenting culture results, susceptibility, and clinical stability before prescribing is likely to be central to whatever stewardship language ends up in the label, particularly given the 2022 CRL history.

What to Watch For

The FDA’s PDUFA decision on oral tebipenem, expected on or before June 18, 2026.
Whether the label restricts use to culture-confirmed resistant Enterobacterales infections.
An IDSA response and any update to its guidance on ESBL-E treatment.
U.S. pricing strategy from GSK; carbapenems are historically low-margin generics, and antibiotic reimbursement reform remains unresolved.
Real-world post-marketing surveillance for carbapenem-resistant organism selection if approval is granted.

Sources

GSK. Positive PIVOT-PO Phase III Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated UTIs. GSK Press Release, October 21, 2025. GSK PIVOT-PO press release (October 2025)
Hong D, et al. Oral Tebipenem Pivoxil Hydrobromide vs Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: PIVOT-PO Phase 3 Results. Open Forum Infectious Diseases, IDWeek 2025 abstract. PIVOT-PO IDWeek 2025 published abstract
Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection (ADAPT-PO). NEJM, April 7, 2022; 386:1327–1338. ADAPT-PO primary results in NEJM
Spero Therapeutics. Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for Complicated Urinary Tract Infections, Including Pyelonephritis. December 19, 2025. Spero Therapeutics December 2025 NDA resubmission release
Urology Times Editorial Staff. What Urologists Can Expect in Q2 of 2026. Urology Times, March 27, 2026. Urology Times Q2 2026 regulatory outlook
Smith JR, Rybak JM. Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections? Contagion Live, December 30, 2025. Contagion Live editorial on oral carbapenems and ESBL
Tamma PD, Aitken SL, Bonomo RA, et al. IDSA Guidance on the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance. Clinical Infectious Diseases, 2021. IDSA 2021 guidance on resistant Gram-negative pathogens
U.S. National Library of Medicine. PIVOT-PO Phase 3 Trial Record (NCT06059846). ClinicalTrials.gov. PIVOT-PO trial record on ClinicalTrials.gov